Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples